Project Grant R01AI189484
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel multivalent mucosal vaccines for human noroviruses. The total funding is $798,173 with a project period from May 1, 2025 to April 30, 2030. The key products and services to be delivered include: 1) Developing multivalent, live-vectored mucosal norovirus vaccines using FDA-approved rotavirus (RotaTeq)...
- This Project Grant award of $233,528 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, supports a systems analysis of immune responses to norovirus infection in a human challenge model. The research aims to delineate the transcriptomic responses in human peripheral blood and stool samples collected from volunteers before and after controlled infection with different strains and doses of norovirus. The goal is to...
- This $107,010 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research into the impact of diet-induced obesity on immune responses to enteric viral infections, specifically norovirus. The principal investigator's preliminary data indicates that mice fed a high-fat diet prior to norovirus infection clear the infection faster than control mice, suggesting obesity may enhance...
- This federal Project Grant award, in the amount of $416,005, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The purpose of the award is to define the molecular mechanisms of human astrovirus (HAstV) entry into human cells, with the goal of identifying targets for the development of vaccines and therapies. The research aims to use structural, biophysical, and virological...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $626,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB). The funding will support research to explore the dependence of arenaviruses on the metabolism of the monosaccharides D-glucose and D-mannose, with the goal of developing carbohydrate antimetabolite compounds as potential pan-arenavirus therapeutics. Specifically,...
- This Project Grant award, valued at $102,444, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The goal of the project is to uncover structural insights into the N-terminal core of the SARS-CoV-2 nonstructural protein 1 (NSP1) and establish its specificity in regulating host gene expression, a process known as "host shutoff." This research aims to advance the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $668,488 Project Grant to The Washington University for the research project "MECHANISMS OF VP4 PROMOTING ROTAVIRUS CELL-TO-CELL TRANSMISSION AND VIRAL PATHOGENESIS" under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project aims to investigate the role of the rotavirus outer capsid protein VP4 in enabling cell-to-cell transmission and viral pathogenesis, with a focus on...
- This $536,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify small molecule inhibitors against critical components of arenaviruses, which cause severe hemorrhagic fevers. The proposed studies aim to use machine learning and molecular screening to identify pan-reactive inhibitors targeting the arenavirus surface glycoprotein and RNA polymerase...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,047,991 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Rector & Visitors of the University of Virginia. The grant, awarded on September 12, 2025, will fund research to investigate the molecular basis for paired receptor signaling in antiviral natural killer (NK) cells during murine cytomegalovirus (MCMV) infection. The research aims to delineate how NK cell receptor...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $831,235 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Southern California (USC) to explore a key nucleotide synthesis enzyme as a potential target for developing broad-spectrum antiviral therapies. The project, led by Co-PIs Pinghui Feng and Chao Zhang, aims to genetically interrogate the enzyme's role in viral immune evasion and metabolic reprogramming...